Article
β-catenin mutation reprograms ketone body metabolism to drive hepatocellular carcinoma metastasis and resistance to ketogenic therapy via transcriptional activation of OXCT1.
Cell death & disease - 9 Mar 2026
Li Huan, Qian Liyuan, Ji Yifan, Geng Yuanhao, Lu Yanjun, Zhang Laizhu, Xu Yanchao, Zong Weiwei, Jiang Xiang, Zhou Xianwei, Wen Jingyuan, Liu Donglin, Wang Ye, Li Yunzheng, Li Binghua, Ma Hucheng, Yu Decai
Abstract excerpt
The ketogenic diet is a controversial approach to cancer therapy. Over 30% of hepatocellular carcinoma (HCC) cases harbor β-catenin activating mutations, among which the S33Y mutation represents a classical hotspot conferring constitutive pathway activation. Our previous metabolic profiling predicted that β-catenin-mutated HCC may exhibit intrinsic resistance to ketogenic therapy. 3-oxoacid CoA-transferase 1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.